Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)

NCT03944772 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

247

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG: Osimertinib
DRUG: Savolitinib
DRUG: Gefitinib
DRUG: Necitumumab
DRUG: Durvalumab
DRUG: Carboplatin
DRUG: Pemetrexed
DRUG: Alectinib
DRUG: Selpercatinib
DRUG: Selumetinib
DRUG: Etoposide
DRUG: Cisplatin
DRUG: Datopotamab deruxtecan

Sponsor

AstraZeneca